JPS4935635B1
(es)
|
1970-12-28 |
1974-09-25 |
|
|
CH563405A5
(es)
|
1971-09-10 |
1975-06-30 |
Duschinsky Robert Dr Schweiz I |
|
DE2226295A1
(de)
|
1972-05-30 |
1973-12-20 |
Henning Berlin Gmbh |
Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
|
DE2342479A1
(de)
|
1973-08-23 |
1975-03-13 |
Merck Patent Gmbh |
Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
|
GB2001976B
(en)
|
1977-08-03 |
1982-03-10 |
Yamasa Shoyu Kk |
S-adenosyl-l-methionine compositions and production thereof
|
US4849311A
(en)
|
1986-09-24 |
1989-07-18 |
Toa Nenryo Kogyo Kabushiki Kaisha |
Immobilized electrolyte membrane
|
US4968697A
(en)
|
1987-02-04 |
1990-11-06 |
Ciba-Geigy Corporation |
2-substituted adenosine 5'-carboxamides as antihypertensive agents
|
US5219840A
(en)
|
1987-04-06 |
1993-06-15 |
Sandoz Ltd. |
Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
|
US5591887A
(en)
|
1987-04-30 |
1997-01-07 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
US5221763A
(en)
|
1987-04-30 |
1993-06-22 |
R-Tech Ueno, Ltd. |
Prostaglandins of the F series
|
ES2317964T5
(es)
|
1988-09-06 |
2015-02-20 |
Pfizer Health Ab |
Derivado de prostaglandina-F2alfa para el tratamiento de glaucoma o hipertensión ocular
|
US5296504A
(en)
|
1988-09-06 |
1994-03-22 |
Kabi Pharmacia |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US6187813B1
(en)
|
1990-04-10 |
2001-02-13 |
Pharmacia & Upjohn Aktiebolag |
Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
|
US5140015A
(en)
|
1990-02-20 |
1992-08-18 |
Whitby Research, Inc. |
2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
|
US5280015A
(en)
|
1990-09-05 |
1994-01-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
|
JP3020580B2
(ja)
|
1990-09-28 |
2000-03-15 |
株式会社日立製作所 |
マイクロ波プラズマ処理装置
|
US5206222A
(en)
|
1991-05-22 |
1993-04-27 |
Vanderbilt University |
Methods for the reduction of myocardial reperfusion injury
|
HU212570B
(en)
|
1991-06-24 |
1996-08-29 |
Chinoin Gyogyszer Es Vegyeszet |
Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
|
US5407793A
(en)
|
1991-10-18 |
1995-04-18 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
An aqueous heart preservation and cardioplegia solution
|
US5278150A
(en)
|
1992-04-24 |
1994-01-11 |
Whitby Research, Inc. |
2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
|
DK62692D0
(es)
|
1992-05-14 |
1992-05-14 |
Novo Nordisk As |
|
WO1994002497A1
(en)
|
1992-07-15 |
1994-02-03 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Sulfo-derivatives of adenosine
|
US5972991A
(en)
|
1992-09-21 |
1999-10-26 |
Allergan |
Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
|
US5338430A
(en)
|
1992-12-23 |
1994-08-16 |
Minnesota Mining And Manufacturing Company |
Nanostructured electrode membranes
|
US5443836A
(en)
|
1993-03-15 |
1995-08-22 |
Gensia, Inc. |
Methods for protecting tissues and organs from ischemic damage
|
DE69428536T2
(de)
|
1993-07-13 |
2002-06-06 |
Nasa |
A3 -adenosin -rezeptor agonisten
|
US5589467A
(en)
|
1993-09-17 |
1996-12-31 |
Novo Nordisk A/S |
2,5',N6-trisubstituted adenosine derivatives
|
WO1995011681A1
(en)
|
1993-10-29 |
1995-05-04 |
Merck & Co., Inc. |
Human adenosine receptor antagonists
|
US5620676A
(en)
|
1994-03-08 |
1997-04-15 |
The United States Of America As Represented By The Department Of Health And Human Services |
Biologically active ATP analogs
|
EP0704215A3
(en)
|
1994-06-02 |
1998-04-01 |
Takeda Chemical Industries, Ltd. |
Inhibitor of vascular permeability enhancer
|
GB9414193D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
US5801159A
(en)
|
1996-02-23 |
1998-09-01 |
Galileo Laboratories, Inc. |
Method and composition for inhibiting cellular irreversible changes due to stress
|
CN1164122A
(zh)
|
1996-03-01 |
1997-11-05 |
株式会社日立制作所 |
等离子处理机及其处理方法
|
WO1997033590A1
(en)
|
1996-03-13 |
1997-09-18 |
Novo Nordisk A/S |
A method of treating disorders related to cytokines in mammals
|
WO1997033879A1
(en)
|
1996-03-15 |
1997-09-18 |
Merck & Co., Inc. |
Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
CA2289731A1
(en)
|
1997-05-09 |
1998-11-12 |
The United States Of America, Represented By The Secretary, Department O F Health And Human Services |
Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
|
US6358536B1
(en)
|
1997-10-15 |
2002-03-19 |
Thomas Jefferson University |
Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
|
US6329349B1
(en)
|
1997-10-23 |
2001-12-11 |
Trustees Of The University Of Pennsylvania |
Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid A and adenosine receptor agents
|
GB9723590D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
GB9723566D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
FR2775901B1
(fr)
|
1998-03-13 |
2000-07-21 |
Logeais Labor Jacques |
Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
|
GB9813535D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
CA2337499A1
(en)
|
1998-07-16 |
2000-01-27 |
The Trustees Of The University Of Pennsylvania |
Methods for reducing intraocular pressure using a3-adenosine antagonists
|
BR9914526A
(pt)
|
1998-10-16 |
2001-07-03 |
Pfizer |
Derivados de adenina
|
IL127947A0
(en)
|
1999-01-07 |
1999-11-30 |
Can Fite Technologies Ltd |
Pharmaceutical use of adenosine agonists
|
US6232297B1
(en)
|
1999-02-01 |
2001-05-15 |
University Of Virginia Patent Foundation |
Methods and compositions for treating inflammatory response
|
US6403567B1
(en)
|
1999-06-22 |
2002-06-11 |
Cv Therapeutics, Inc. |
N-pyrazole A2A adenosine receptor agonists
|
US6180615B1
(en)
|
1999-06-22 |
2001-01-30 |
Cv Therapeutics, Inc. |
Propargyl phenyl ether A2A receptor agonists
|
US6214807B1
(en)
|
1999-06-22 |
2001-04-10 |
Cv Therapeutics, Inc. |
C-pyrazole 2A A receptor agonists
|
CN1166677C
(zh)
|
1999-06-22 |
2004-09-15 |
Cv治疗公司 |
噻吩a2a受体激动剂
|
IL133680A0
(en)
|
1999-09-10 |
2001-04-30 |
Can Fite Technologies Ltd |
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
US6368573B1
(en)
|
1999-11-15 |
2002-04-09 |
King Pharmaceuticals Research And Development, Inc. |
Diagnostic uses of 2-substituted adenosine carboxamides
|
US6258793B1
(en)
|
1999-12-03 |
2001-07-10 |
Cv Therapeutics, Inc. |
N6 heterocyclic 5′ modified adenosine derivatives
|
GB9930071D0
(en)
|
1999-12-20 |
2000-02-09 |
Glaxo Group Ltd |
Medicaments
|
GB0003960D0
(en)
|
2000-02-18 |
2000-04-12 |
Pfizer Ltd |
Purine derivatives
|
US20010051612A1
(en)
|
2000-02-23 |
2001-12-13 |
Gloria Cristalli |
2-Thioether A2A receptor agonists
|
US20030010454A1
(en)
|
2000-03-27 |
2003-01-16 |
Bailey Andrew D. |
Method and apparatus for varying a magnetic field to control a volume of a plasma
|
US6534651B2
(en)
|
2000-04-06 |
2003-03-18 |
Inotek Pharmaceuticals Corp. |
7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
CN1450896A
(zh)
|
2000-07-28 |
2003-10-22 |
印斯拜尔药品股份有限公司 |
用吲哚衍生物降低眼内压的方法
|
ATE292973T1
(de)
|
2001-01-16 |
2005-04-15 |
Can Fite Biopharma Ltd |
Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
|
GB2372742A
(en)
|
2001-03-03 |
2002-09-04 |
Univ Leiden |
C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
|
EP1241176A1
(en)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Purine derivatives for the treatment of ischemia
|
US20040204481A1
(en)
|
2001-04-12 |
2004-10-14 |
Pnina Fishman |
Activation of natural killer cells by adenosine A3 receptor agonists
|
US20030013675A1
(en)
|
2001-05-25 |
2003-01-16 |
Boehringer Ingelheim Pharma Kg |
Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
|
US7713946B2
(en)
|
2002-07-11 |
2010-05-11 |
Cv Therapeutics, Inc. |
Partial and full agonists A1 adenosine receptors
|
EP1423175B1
(en)
|
2001-08-08 |
2013-10-02 |
Brown University Research Foundation |
Methods for micronization of hydrophobic drugs
|
CA2460911C
(en)
|
2001-10-01 |
2011-08-30 |
University Of Virginia Patent Foundation |
2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
|
JP2005530736A
(ja)
|
2002-04-18 |
2005-10-13 |
シーブイ・セラピューティクス・インコーポレイテッド |
ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にa1アデノシンアゴニストを投与することを含む不整脈の処置方法
|
AU2003221762B2
(en)
|
2002-04-30 |
2008-09-25 |
Alcon, Inc. |
Agents which regulate, inhibit or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
|
GB0216416D0
(en)
|
2002-07-15 |
2002-08-21 |
Novartis Ag |
Organic compounds
|
US20060034941A1
(en)
|
2002-12-23 |
2006-02-16 |
Global Cardiac Solutions Pty Ltd |
Organ preconditioning, arrest, protection, preservation and recovery
|
GB2436255B
(en)
|
2002-12-23 |
2007-11-28 |
Global Cardiac Solutions Pty L |
Organ preconditioning, arrest, protection, preservation and recovery
|
US8008338B2
(en)
*
|
2003-06-03 |
2011-08-30 |
Allergan, Inc. |
Ketorolac tromethamine compositions for treating or preventing ocular pain
|
CA2554716A1
(en)
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
MXPA06013560A
(es)
|
2004-05-26 |
2007-03-15 |
Inotek Pharmaceuticals Corp |
Derivados de purina como agonistas del receptor de adenosina a1 y metodos de uso de los mismos.
|
CN101010085B
(zh)
|
2004-05-26 |
2012-12-26 |
伊诺泰克制药公司 |
嘌呤衍生物作为腺苷a1受体激动剂及其用法
|
US7271157B2
(en)
|
2004-07-12 |
2007-09-18 |
Cv Therapeutics, Inc. |
A1 adenosine receptor agonists
|
WO2007002139A2
(en)
|
2005-06-22 |
2007-01-04 |
The Trustees Of The University Of Pennsylvania |
Neuroprotection of retinal ganglion cells
|
JP5203214B2
(ja)
|
2005-11-30 |
2013-06-05 |
イノテック ファーマシューティカルズ コーポレイション |
プリン化合物およびその使用方法
|
ES2385924T3
(es)
|
2006-02-02 |
2012-08-03 |
Allergan, Inc. |
Inhibidores de la actividad de CXCR4 para su uso en el tratamiento de trastornos oculares
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
BRPI0709124A2
(pt)
|
2006-03-23 |
2011-06-28 |
Inotek Pharmaceuticals Corp |
composto purina e métodos de uso dos mesmos
|
US8163737B2
(en)
|
2006-06-13 |
2012-04-24 |
Vertex Pharmaceuticals Incorporated |
CGRP receptor antagonists
|
CA2658646A1
(en)
|
2006-07-25 |
2008-01-31 |
Osmotica Corp. |
Ophthalmic solutions
|
AU2007307157A1
(en)
|
2006-10-06 |
2008-04-17 |
The Trustees Of The University Of Pennsylvania |
Effective delivery of cross-species A3 adenosine-receptor antagonists to reduce intraocular pressure
|
SI2083629T2
(sl)
*
|
2006-11-10 |
2015-03-31 |
Basf Se |
Kristalna modifikacija fipronila
|
JP5576659B2
(ja)
|
2006-12-05 |
2014-08-20 |
ザ ロイヤル インスティテューション フォー ジ アドバンスメント オブ ラーニング/ マギル ユニバーシティ |
Trkレセプター調節因子の使用方法
|
WO2008096804A1
(ja)
*
|
2007-02-07 |
2008-08-14 |
Teika Pharmaceutical Co., Ltd. |
ラタノプロスト含有点眼剤
|
JP2008266143A
(ja)
|
2007-04-16 |
2008-11-06 |
Santen Pharmaceut Co Ltd |
アデノシン誘導体を有効成分として含有する緑内障治療剤
|
WO2009048605A1
(en)
|
2007-10-11 |
2009-04-16 |
Biogen Idec Ma Inc. |
Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
|
US20100272711A1
(en)
|
2007-12-12 |
2010-10-28 |
Thomas Jefferson University |
Compositions and methods for the treatment and prevention of cardiovascular diseases
|
CA2714516A1
(en)
|
2008-02-07 |
2009-08-13 |
Gilead Palo Alto, Inc. |
Abca-1 elevating compounds and the use thereof
|
CN102215869B
(zh)
|
2008-11-13 |
2015-05-13 |
通用医疗公司 |
用于通过调整bmp-6来调节铁稳态的方法和组合物
|
PL2424546T3
(pl)
|
2009-05-01 |
2016-04-29 |
Inotek Pharmaceuticals Corp |
Sposób obniżania ciśnienia wewnątrzgałkowego u ludzi
|
KR101690816B1
(ko)
*
|
2009-06-25 |
2016-12-28 |
라이온 가부시키가이샤 |
안과용 조성물 및 백탁·침전 억제 방법
|
BR112012009841A2
(pt)
*
|
2009-10-26 |
2016-11-29 |
Inotek Pharmaceuticals Corp |
formulação oftálmica e processo para a sua preparação
|
WO2011077435A1
(en)
|
2009-12-22 |
2011-06-30 |
Bar-Ilan University |
Compositions and methods for reducing intraocular pressure
|
EP2523669B1
(en)
|
2010-01-11 |
2016-12-07 |
Inotek Pharmaceuticals Corporation |
Combination, kit and method of reducing intraocular pressure
|
US20110217262A1
(en)
|
2010-03-05 |
2011-09-08 |
Kornfield Julia A |
Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
|
ES2613254T3
(es)
|
2010-03-19 |
2017-05-23 |
Inotek Pharmaceuticals Corporation |
Composiciones de combinación de agonistas de adenosina A1 e inhibidores de anhidrasa carbónica para reducir la presión intraocular
|
RS55616B1
(sr)
|
2010-03-19 |
2017-06-30 |
Inotek Pharmaceuticals Corp |
Kombinovane kompozicije adenozinskih a1 agonista i ne-selektivnih beta-adrenergičnih receptor blokera za snižavanje intraokularnog pritiska
|
US8501708B2
(en)
|
2010-03-26 |
2013-08-06 |
Inotek Pharmaceuticals Corporation |
Adenosine compounds and their use thereof
|
WO2011119969A1
(en)
|
2010-03-26 |
2011-09-29 |
Inotek Pharmaceuticals Corporation |
Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
|
US20140241990A1
(en)
|
2011-09-30 |
2014-08-28 |
Tufts University |
Methods of using adenosine a1 receptor activation for treating depression
|
US9278991B2
(en)
*
|
2012-01-26 |
2016-03-08 |
Inotek Pharmaceuticals Corporation |
Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
|
BR112015022044A2
(pt)
|
2013-03-15 |
2017-07-18 |
Inotek Pharmaceuticals Corp |
um método de proporcionar neutroproteção ocular
|